Effect of Sphenopalatine Ganglion Block With Bupivacaine on Postoperative Pain in Patients Undergoing Endoscopic Pituitary Adenoma Resection

Trial ID: NCT06353529

Interventional - Phase 4 - Recruiting

To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.

Conditions

• Pituitary
• Pain, Postoperative

Interventions

• Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
• Placebo
• Sham Comparator

Eligibility

Inclusion criteria

• adult patients (18 yrs or older)
• undergoing endonasal pituitary adenoma resection

Exclusion criteria

• Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs
• contraindications to the performance of SPGB such as known allergy to used medications
• chronic alcohol abuse
• uncontrolled systemic arterial hypertension
• severe kidney or liver diseases
• cardiomyopathies or sustained cardiac arrhythmias (permanent paroxystic atrial fibrillation or other sustained supraventricular rhythmic anomalies)

Sponsor

Hamilton Health Sciences Corporation

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows